NanoViricides, Inc. (NNVC)
USD 1.5
(0.67%)
USD 1.5
(0.67%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -4.79 Million USD | 41.13% |
| 2023 | -8.14 Million USD | 41.67% |
| 2022 | -13.97 Million USD | 31.58% |
| 2021 | -20.42 Million USD | -62.54% |
| 2020 | -12.56 Million USD | -391.69% |
| 2019 | -2.55 Million USD | 63.92% |
| 2018 | -7.08 Million USD | 36.45% |
| 2017 | -11.14 Million USD | 28.36% |
| 2016 | -15.55 Million USD | 35.96% |
| 2015 | -24.28 Million USD | 12.19% |
| 2014 | -27.65 Million USD | -164.55% |
| 2013 | -10.45 Million USD | 26.76% |
| 2012 | -14.27 Million USD | -54.76% |
| 2011 | -9.22 Million USD | -32.61% |
| 2010 | -6.95 Million USD | -311.72% |
| 2009 | -1.68 Million USD | -106.94% |
| 2008 | -816.38 Thousand USD | 15.64% |
| 2007 | -967.79 Thousand USD | 39.13% |
| 2006 | -1.59 Million USD | 0.0% |
| 2005 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -5.46 Million USD | 32.88% |
| 2024 Q4 | -4.79 Million USD | -47.3% |
| 2024 Q3 | -3.25 Million USD | 37.9% |
| 2024 Q2 | -5.24 Million USD | 4.1% |
| 2023 FY | -8.14 Million USD | 41.67% |
| 2023 Q3 | -9.65 Million USD | 15.7% |
| 2023 Q2 | -11.44 Million USD | 11.21% |
| 2023 Q1 | -12.89 Million USD | 7.71% |
| 2023 Q4 | -8.14 Million USD | 15.55% |
| 2022 FY | -13.97 Million USD | 31.58% |
| 2022 Q2 | -17.33 Million USD | 11.88% |
| 2022 Q4 | -13.97 Million USD | 9.32% |
| 2022 Q3 | -15.4 Million USD | 11.13% |
| 2022 Q1 | -19.67 Million USD | 3.67% |
| 2021 FY | -20.42 Million USD | -62.54% |
| 2021 Q2 | -18.39 Million USD | 11.08% |
| 2021 Q1 | -20.68 Million USD | -64.63% |
| 2021 Q3 | -22.73 Million USD | -23.6% |
| 2021 Q4 | -20.42 Million USD | 10.17% |
| 2020 Q3 | -4.92 Million USD | -1488.28% |
| 2020 Q2 | 354.68 Thousand USD | 140.54% |
| 2020 FY | -12.56 Million USD | -391.69% |
| 2020 Q1 | -874.95 Thousand USD | 65.76% |
| 2020 Q4 | -12.56 Million USD | -155.15% |
| 2019 Q2 | -3.9 Million USD | 35.82% |
| 2019 FY | -2.55 Million USD | 63.92% |
| 2019 Q1 | -6.08 Million USD | 14.11% |
| 2019 Q3 | -4.23 Million USD | -8.53% |
| 2019 Q4 | -2.55 Million USD | 39.69% |
| 2018 Q4 | -7.08 Million USD | 33.3% |
| 2018 Q2 | -6.88 Million USD | 26.09% |
| 2018 Q3 | -10.61 Million USD | -54.19% |
| 2018 Q1 | -9.31 Million USD | 16.39% |
| 2018 FY | -7.08 Million USD | 36.45% |
| 2017 FY | -11.14 Million USD | 28.36% |
| 2017 Q4 | -11.14 Million USD | 10.3% |
| 2017 Q3 | -12.42 Million USD | -25.9% |
| 2017 Q2 | -9.86 Million USD | 23.52% |
| 2017 Q1 | -12.9 Million USD | 17.06% |
| 2016 Q1 | -21.96 Million USD | 9.56% |
| 2016 Q2 | -20.37 Million USD | 7.25% |
| 2016 Q3 | -17.36 Million USD | 14.75% |
| 2016 Q4 | -15.55 Million USD | 10.45% |
| 2016 FY | -15.55 Million USD | 35.96% |
| 2015 Q3 | -27.05 Million USD | 5.7% |
| 2015 Q1 | -33.46 Million USD | -21.0% |
| 2015 FY | -24.28 Million USD | 12.19% |
| 2015 Q4 | -24.28 Million USD | 10.23% |
| 2015 Q2 | -28.68 Million USD | 14.28% |
| 2014 Q3 | -29.37 Million USD | -122.41% |
| 2014 FY | -27.65 Million USD | -164.55% |
| 2014 Q4 | -27.65 Million USD | 5.85% |
| 2014 Q1 | -15.6 Million USD | -49.22% |
| 2014 Q2 | -13.2 Million USD | 15.33% |
| 2013 Q3 | -12.11 Million USD | 12.69% |
| 2013 Q1 | -12.92 Million USD | 9.42% |
| 2013 FY | -10.45 Million USD | 26.76% |
| 2013 Q4 | -10.45 Million USD | 13.73% |
| 2013 Q2 | -13.87 Million USD | -7.35% |
| 2012 Q2 | -12.09 Million USD | -11.21% |
| 2012 Q1 | -10.87 Million USD | -17.95% |
| 2012 Q4 | -14.27 Million USD | -9.94% |
| 2012 FY | -14.27 Million USD | -54.76% |
| 2012 Q3 | -12.98 Million USD | -7.32% |
| 2011 FY | -9.22 Million USD | -32.61% |
| 2011 Q4 | -9.22 Million USD | -18.81% |
| 2011 Q3 | -7.76 Million USD | 13.69% |
| 2011 Q2 | -8.99 Million USD | -17.16% |
| 2011 Q1 | -7.67 Million USD | -10.38% |
| 2010 Q3 | -2.94 Million USD | 26.9% |
| 2010 FY | -6.95 Million USD | -311.72% |
| 2010 Q2 | -4.03 Million USD | 4.04% |
| 2010 Q4 | -6.95 Million USD | -135.95% |
| 2010 Q1 | -4.2 Million USD | -148.76% |
| 2009 Q2 | -1.93 Million USD | 35.16% |
| 2009 Q4 | -1.68 Million USD | -37.57% |
| 2009 FY | -1.68 Million USD | -106.94% |
| 2009 Q1 | -2.98 Million USD | -265.67% |
| 2009 Q3 | -1.22 Million USD | 36.56% |
| 2008 Q1 | 32.01 Million USD | -50.0% |
| 2008 Q2 | -1.92 Million USD | -106.02% |
| 2008 Q3 | -1.21 Million USD | 37.22% |
| 2008 Q4 | -816.38 Thousand USD | 32.58% |
| 2008 FY | -816.38 Thousand USD | 15.64% |
| 2007 Q3 | 27.88 Million USD | -47.73% |
| 2007 Q2 | 53.35 Million USD | 3101.59% |
| 2007 FY | -967.79 Thousand USD | 39.13% |
| 2007 Q1 | -1.77 Million USD | -11.79% |
| 2007 Q4 | 64.03 Million USD | 129.61% |
| 2006 Q4 | -1.59 Million USD | 0.0% |
| 2006 FY | -1.59 Million USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -4.94 Million USD | 2.958% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | -25.761% |
| Armata Pharmaceuticals, Inc. | 106.84 Million USD | 104.49% |
| Actinium Pharmaceuticals, Inc. | -74.56 Million USD | 93.566% |
| Azitra, Inc. | -910.04 Thousand USD | -427.204% |
| Can-Fite BioPharma Ltd. | -4.23 Million USD | -13.209% |
| Chromocell Therapeutics Corporation | 1.17 Million USD | 509.264% |
| Calidi Biotherapeutics, Inc. | 5.18 Million USD | 192.496% |
| CEL-SCI Corporation | 9.42 Million USD | 150.899% |
| iBio, Inc. | -9.75 Million USD | 50.792% |
| Lineage Cell Therapeutics, Inc. | -32.49 Million USD | 85.233% |
| MAIA Biotechnology, Inc. | -7.15 Million USD | 32.905% |
| Matinas BioPharma Holdings, Inc. | -1.28 Million USD | -274.534% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | 1194.274% |
| NovaBay Pharmaceuticals, Inc. | -390 Thousand USD | -1130.199% |
| Oragenics, Inc. | -3.17 Million USD | -51.311% |
| BiomX Inc. | -772 Thousand USD | -521.474% |
| BiomX Inc. | -772 Thousand USD | -521.474% |
| Protalix BioTherapeutics, Inc. | 2.64 Million USD | 281.253% |
| Palatin Technologies, Inc. | -8.93 Million USD | 46.316% |
| Scorpius Holdings, Inc. | 13.85 Million USD | 134.623% |